...and all have held managerial roles at Mabpharm subsidiaries Taizhou Mabtech Biotechnology Ltd. and Taizhou Mabtech...

...and all have held managerial roles at Mabpharm subsidiaries Taizhou Mabtech Biotechnology Ltd. and Taizhou Mabtech...

...III Sorrento Therapeutics Inc. (NASDAQ:SRNE) Four biosimilar mAbs for cancer and autoimmune indications licensed from Mabtech Ltd....

...irinotecan alone. Mabtech plans to submit a regulatory application in China for STI-001. Last year, Mabtech...
...biosimilar mAbs, including STI-001, in North America, Europe and Japan (see BioCentury, Sept. 7, 2015). Mabtech Ltd....

...Remicade infliximab. Mabtech plans to submit a regulatory application in China for STI-002. Last year, Mabtech...
...biosimilar mAbs, including STI-002, in North America, Europe and Japan (see BioCentury, Sept. 7, 2015). Mabtech Ltd....

...review in China. Sorrento did not respond to inquiries, and Mabtech could not be reached. Mabtech Ltd....

...Corporate partners: NA Employees: 24 Funds raised: £10 million ($18.6 million) Investors: Prelude Ventures; Quester; Mabtech...

...with its antibody-drug conjugate (ADC) technology. Under a 1998 deal, SGEN licensed rights to a Mabtech...
...companies expect to start clinical testing later this year. Seattle Genetics Inc. (SGEN), Bothell, Wash. Mabtech...

...with its antibody-drug conjugate (ADC) technology. Under a 1998 deal, SGEN licensed rights to a Mabtech...